LongSeven (recombinant liposomal factor VIIa) / Recoly - LARVOL DELTA

Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors (Blood Coagul Fibrinolysis) - P=NA, N=6; "Haemostasis was assessed by prothrombin time (PT), activated partial thromboplastin time (aPTT), factor VII coagulant activity (FVII:C), TEG, and TGA. Six out of seven (85.7%) bleeding episodes responded to conventional rFVIIa dosing, and half (50%) responded to the high-dose regimen. No relationships between PT, aPTT, and FVII:C levels and clinical outcome were observed. However, changes in TEG and TGA parameters tended to correspond to clinical response, although large inter-individual variation in rFVIIa efficacy was noted."

Clinical data • Hemophilia